AMLX
Amylyx Pharmaceuticals, Inc. [AMLX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AMLX Stock Summary
Top 10 Correlated ETFs
AMLX
Top 10 Correlated Stocks
AMLX
In the News
AMLX Financial details
Company Rating
-
Market Cap
142.34M
Income
49.27M
Revenue
380.79M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
384
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
602.18
Forward P/E
-
PEG
-48.32
P/S
3.76
P/B
2.64
P/C
-
P/FCF
-20.95
Quick Ratio
8.43
Current Ratio
9.52
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.73
EPS next Y
-
EPS next Q
-
EPS this Y
-124.5%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
205.71%
Revenue Q/Q
5.61%
EPS Q/Q
-77.35%
-
-
-
-
SMA20
1.08%
SMA50
4.46%
SMA100
-29.51%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-0.02%
Gross Margin
94%
Oper. Margin
-3%
Profit Margin
1%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.07-31.77
52W High
-86.35%
52W Low
+111.5%
RSI
64.42
Rel Volume
0.29
Avg Volume
3.14M
Volume
895.38K
Perf Week
21.2%
Perf Month
9.3%
Perf Quarter
-13.67%
Perf Half Y
-9.23%
-
-
-
-
Beta
-0.93
-
-
Volatility
0.22%, 0.2%
Prev Close
6.28%
Price
4.23
Change
10.44%
Company Profile
- Volume Average 3.14M
- Market Capitalization 142.34M
- Employee 384
- CEO Mr. Joshua B. Cohen
- Headquarters Cambridge,MA,US
- IPO Date 2022-01-07
-
Website
https://amylyx.com 
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
